TiMi AI
A 16% Jump on Earnings Day
IDEXX Laboratories was trading at $640.01 as of 2 November 2026 at 16:02 UTC, up 16.32% against the previous close, after the company reported third-quarter results that cleared Wall Street expectations on both the top and bottom lines. IDEXX's own Q3 release, filed with the SEC as an 8-K exhibit on 2 November 2026, is the official record and describes the quarter as delivering "exceptional third quarter results."
For the quarter ended September 2026, IDEXX reported revenue of $1.21 billion, up 10% year over year, against a consensus estimate of $1.19 billion — a beat of 2.21%. Adjusted earnings per share came in at $3.96, ahead of the analyst consensus of roughly $3.71–$3.72. Reported EPS of $4.01 represented an 18% increase year over year. The company also placed over 1,900 inVue Dx analyzers during the quarter, bringing the installed base to nearly 11,000 instruments, with Companion Animal Group diagnostics recurring revenue growing 11% as reported and organically.
Beyond the quarter itself, IDEXX raised its full-year 2026 revenue guidance to a range of $4.74 billion to $4.77 billion, with a midpoint above the prior analyst consensus of $4.72 billion. The company also lifted its full-year EPS outlook to $14.96 to $15.16, compared to a consensus of $14.88. The session's gain coincided with strong recurring CAG revenue, higher testing utilization, and continued adoption of IDEXX's diagnostic innovations.
The surge follows a roughly 4% decline on 30 October 2026. That earlier drop came days after a price target cut by a major bank.
A Low Base and a Clean Beat
The one-month low of $499.88 illustrates how compressed the stock had become before results arrived. The 16.32% single-session gain came as the stock rose from near that low base, coinciding with a quarter in which revenue grew 10%, EPS grew 18%, and guidance was raised.
Over the past year, IDEXX had been a laggard, with the stock carrying a negative one-year return heading into the print. The Q3 report gave the market a concrete reason to reassess that discount.
Guidance Range Now the Anchor
With the Q3 report now filed and confirmed, the raised full-year 2026 revenue guidance range of $4.74 billion to $4.77 billion becomes the near-term reference point. Whether the stock can hold above $640.01 will depend on whether subsequent quarters sustain the recurring revenue trajectory that drove the beat.
The one-month high of $660.77 sits just above current levels, making that a near-term reference. According to trefis.com, IDEXX's largest one-day post-earnings reactions over the past five years reached +27.5% on the upside and -9.8% on the downside, a range that puts the current session's 16.32% gain in historical context.
Risk Factors
- Post-earnings volatility: a 16.32% single-session surge creates elevated risk of mean reversion, particularly given the stock's history of sharp post-earnings reversals of up to -9.8% in prior quarters.
- Foreign currency headwinds: international CAG revenues grew faster organically than as reported, signaling that currency translation remains a drag on headline results.
- Guidance execution risk: the raised full-year 2026 revenue range of $4.74 billion to $4.77 billion leaves limited room for error in Q4, and the stock's history shows single-session declines of up to -9.8% following earnings releases.
- Valuation reset: the stock was trading near its 52-week low before the report; the sharp recovery puts pressure on the business to sustain double-digit recurring revenue growth.
This article does not constitute financial advice. Prices quoted reflect a live market observation as of 2 November 2026 at 16:02 UTC and are not closing prices. Past performance is not indicative of future results.
This article was generated with AI assistance and may contain errors.
